Journal article
Biologic Frameworks for Synucleinopathies: Contributions of the Parkinson's Progression Markers Initiative
Annals of neurology
05/06/2026
DOI: 10.1002/ana.78249
PMID: 42089472
Abstract
A research biologic definition and staging of neuronal alpha-synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, is critical toward improving clinical trial design and drug development. Neuronal synuclein disease, and the companion Integrated Staging System, are a biologic definition and staging system conceptualized by multiple stakeholders including academia, industry, advocacy organizations, and importantly, people with lived experiences. In large part, this was informed and enabled by the knowledge garnered from the Parkinson's Progression Markers Initiative. This review provides a historical perspective and details contributions from the Parkinson's Progression Markers Initiative, among others, that made this advancement possible. These include the key role it played in validation of an in vivo biomarker of neuronal alpha-synuclein, longitudinal characterization of dopaminergic dysfunction imaging, biospecimen collection and assays, comprehensive genetic characterization, and clinical phenotyping. In addition, the Parkinson's Progression Markers Initiative is generating and sharing data that will be used to address key gaps in knowledge, revisions, and future refinements of a biologic definition and staging of synucleinopathies. ANN NEUROL 2026.
Details
- Title: Subtitle
- Biologic Frameworks for Synucleinopathies: Contributions of the Parkinson's Progression Markers Initiative
- Creators
- Lana M Chahine - University of PittsburghRoy N Alcalay - Columbia University Irving Medical CenterEthan G Brown - University of California, San FranciscoSohini Chowdhury - Michael J. Fox FoundationChristopher S Coffey - University of IowaTatiana Foroud - Indiana University School of MedicineMark Frasier - Michael J. Fox FoundationDouglas Galasko - University of California San DiegoKalpana M Merchant - Northwestern UniversityBrit Mollenhauer - Paracelsus Elena Klinik KasselEduardo Tolosa - Consorci Institut D'Investigacions Biomediques August Pi I SunyerNicola Pavese - Newcastle UniversityThomas F Tropea - Institute for Neurodegenerative DisordersKenneth Marek - Institute for Neurodegenerative DisordersTanya Simuni - Northwestern UniversityParkinson's Progression Markers Initiative
- Resource Type
- Journal article
- Publication Details
- Annals of neurology
- DOI
- 10.1002/ana.78249
- PMID
- 42089472
- ISSN
- 1531-8249
- eISSN
- 1531-8249
- Publisher
- Wiley
- Grant note
- PPMI - Michael J. Fox Foundation for Parkinson's Research AbbVie BIAL Critical Path Institute Edmond J. Safra Foundation Eli Lilly, Gain Therapeutics GE HealthCare Voyager Therapeutics Weston Family Foundation
PPMI, a public-private partnership, is funded by The Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Alamar Biosciences, Aligning Science Across Parkinson's, Arrowhead Pharma, AskBio, BIAL, BioArctic, Biohaven, BlueRock Therapeutics, Bristol-MyersSquibb, Calico Labs, Capsida Biotherapeutics, Critical Path Institute, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Insitro, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Neumora, Neuron23, Novartis, Regeneron, Roche, Sanofi, Tenvie, UCB, VanquaBio, Voyager Therapeutics, and the Weston Family Foundation.
- Language
- English
- Electronic publication date
- 05/06/2026
- Academic Unit
- Biostatistics
- Record Identifier
- 9985161340802771
Metrics
1 Record Views